Adjuvant Chemoimmunotherapy of Head and Neck Cancer

  • S. G. Taylor
  • G. A. Sisson
  • D. E. Bytell
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)


Adjuvant systemic therapy in head and neck cancer has not been actively studied because regional recurrences have focused attention on the need for improved regional therapy and because additive toxicity with radiation therapy has discouraged use of effective regimens of chemotherapy. Randomized multi-institution studies have shown no differences in disease-free survival after 2 years [15, 28]. However, improved disease-free survival for the first 8–12 months was observed in a few studies [14, 21]. Such a duration of effect from methotrexate in the treatment of gross residual disease would be unusual and suggested that a more aggressive approach to adjuvant treatment might yield more long-lasting beneficial results. With improved local control from more effective surgery and radiation therapy, systemic metastases have caused an increased percentage of treatment failures accentuating the need to re-examine systemic adjuvant therapy [13]. Response rates to chemotherapy have also improved with the use of methotrexate and leucovorin in a weekly schedule [20] and use of combination drug therapy [3] although duration of response remains short. These developments are background to our current approach to adjuvant therapy trials.


Neck Cancer Prognostic Category Advanced Squamous Cell Carcinoma Follow Radiation Therapy Tumor Cell Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Joint Committee for Cancer Staging and End Results Reporting. Chicago (Ill.) 1965, 1972, 1976.Google Scholar
  2. 2.
    Bekesi, J. G., Holland, J. F., Roboz, J. P.: Specific immunotherapy with neuraminidase-modified leukemia cells. Med. Clin. North Am. 61, 1083–1100 (1977).PubMedGoogle Scholar
  3. 3.
    Caradonna, R., Paladine, W., Goldstein, J. et al.: Combination chemotherapy with high dose cis-diammine-dichloroplatinum (II), methotrexate, and bleomycin for epidermoid carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. C 378, 401 (1978).Google Scholar
  4. 4.
    Catalona, W. J., Sample, W. F., Chretien, P. B.: Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage. Cancer 31, 65–70 (1973).PubMedCrossRefGoogle Scholar
  5. 5.
    Chandler, J. R., Guillamondegui, O. M., Sisson, G. A. et al.: Clinical staging of cancer of the head and neck: A new “new” system. Am. J. Surg. 132, 525–528 (1976).PubMedCrossRefGoogle Scholar
  6. 6.
    DeConti, R. C.: Phase III comparison of methotrexate with leucovorin vs. methotrexate alone vs. a combination of methotrexate plus leucovorin, cyclophosphamide and cytosine arabinoside in head and neck cancer. Proc. Am. Soc. Clin. Oncol. C 46, 248 (1976).Google Scholar
  7. 7.
    Donaldson, R. C.: Methotrexate plus bacillus Calmette-Guerin (BCG) and isoniazid in the treatment of cancer of the head and neck. Am. J. Surg. 124, 527–534 (1972).PubMedCrossRefGoogle Scholar
  8. 8.
    Donaldson, R. C.: Chemoimmunotherapy for cancer of the head and neck. Am. J. Surg. 126, 507–512 (1973).PubMedCrossRefGoogle Scholar
  9. 9.
    Donaldson, R., Banda, F., Keehn, R.: Methotrexate plus MER for head and neck cancer. Immunity: Solid tumor therapy. Crispen, R. G. (ed.), pp. 243-248. Franklin Inst. 1977.Google Scholar
  10. 10.
    Eilber, F. R., Morton, D. L.: Adjuvant chemoimmunotherapy in advanced lesions of the head and neck. Am. J. Roentgenol. Rad. Ther. Nucl. Med. 126, 1082–1087 (1976).Google Scholar
  11. 11.
    Feinstein, A. R.: Clinical Biostatistics. pp. 385-413. St. Louis: C. V. Mosby 1977.Google Scholar
  12. 12.
    Froese, G., Berczi, I., Sehon, A. H.: Neuraminidase-induced enhancement of tumor growth in mice. J. Natl. Cancer Inst. 52, 1905–1908 (1974).PubMedGoogle Scholar
  13. 13.
    Jesse, R. H., Lindberg, R. D.: The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastatis from squamous cancer of the oropharynx and hypopharynx. Cancer 35, 1163–1166 (1975).PubMedCrossRefGoogle Scholar
  14. 14.
    Knowlton, A. H., Percarpio, B., Bobrow, S. et al.: Methotrexate and radiation therapy in the treatment of advanced head and neck tumors. Radiology 116, 709–712 (1975).PubMedGoogle Scholar
  15. 15.
    Kramer, S.: Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx, and hypopharynx. Can. J. Otolaryngol. 4, 213–218 (1975).PubMedGoogle Scholar
  16. 16.
    McKneally, M. F., Maver, C.: Regional immunotherapy using intrapleural BCG and isoniazid for resectable lung cancer: Results in the first 100 cases. In: Adjuvant therapy of cancer. Salmon, S. E., Jones, S. E. (eds.), pp. 207-216. Amsterdam: Elsevier/North Holland 1977.Google Scholar
  17. 17.
    Pellis, N. R., Kahan, B. D.: Specific tumor immunity induced with soluble materials: Restricted range of antigen dose and of c challenge tumor load for immunoprotection. J. Immunol. 115, 1717–1722 (1975).PubMedGoogle Scholar
  18. 18.
    Peto, R., Pike, M. C., Armitage, P. et al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer 34, 585–612 (1976).PubMedCrossRefGoogle Scholar
  19. 19.
    Pitman, S., Landwehr, D., Jaffe, N., Frei, E., III: Methotrexate citrovorum: Effect of alkalinization on nephrotoxicity and of weekly schedule on response. Proc. Amer. Assoc. Cancer Res. 17, 129 (1976).Google Scholar
  20. 20.
    Pitman, S. W., Miller, D., Weichselbaum, R., Frei, E., III: Weekly high dose methotrexate with leucovorin rescue as initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck: A pilot study. In: Adjuvant therapy of Cancer. Salmon, S. E., Jones, S. E. (eds.). Amsterdam: North Holland 1977.Google Scholar
  21. 21.
    Richard, J. M., Sancho, H., Lepintre, Y. et al.: Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. Cancer 34, 491–496 (1974).PubMedCrossRefGoogle Scholar
  22. 22.
    Richman, S. P., Livingston, R. B., Gutterman, J. U. et al.: Chemotherapy versus chemoimmunotherapy of head and neck cancer: Report of a randomized study. Cancer Treat. Rep. 60, 535–539 (1976).PubMedGoogle Scholar
  23. 23.
    Rios, A., Simmons, R. L.: Experimental cancer immunotherapy using a neuraminidase-treated non-viable frozen tumor vaccine. Surgery 75, 503–507 (1974).PubMedGoogle Scholar
  24. 24.
    Sisson, G. A., Bytell, D. E., Becker, S. P.: Mediastinal — 1976: Indications and new techniques. Laryngoscope 87, 751–759 (1977).PubMedCrossRefGoogle Scholar
  25. 25.
    Sparks, F. C., Breeding, J. H.: Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guerin and neuraminidase. Cancer Res. 34, 3262–3269 (1974).PubMedGoogle Scholar
  26. 26.
    Taylor, S., Bytell, D., Sisson, G. A. et al.: Chemoimmunotherapy as adjuvant to surgery and radiotherapy in stage III–IV head and neck squamous cancer patients. Neoplasm immunity: solid tumor therapy. Crispen, R. G. (ed.), pp. 249-266. Chicago: Franklin Inst. 1977.Google Scholar
  27. 27.
    Taylor, S. G., IV, Bytell, D. E., DeWys, W. D.: Adjuvant methotrexate and leucovorin in head and neck squamous cancer. Arch. Otolaryngology (1978) (to be published).Google Scholar
  28. 28.
    von Essen, C. F., Joseph, L., Simon, G. et al.: Sequential chemotherapy and radiation therapy of buccal mucosa carcinoma in So. India. Am. J. Roentgenol. Radium Ther. Nucl. Med. 102, 530–540 (1968).Google Scholar
  29. 29.
    Wanebo, H. J., Hilal, E. Y., Strong, E. W.: Randomized trial of levamisole in patients with squamous cancer of head and neck. Am. Soc. Clin. Oncology C 189 (1978).Google Scholar
  30. 30.
    Woods, J. E., DeSanto, L. W., Ritts, R. E. (Jr.): A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck. Surg. Clin. North Am. 57, 769–778 (1977).PubMedGoogle Scholar
  31. 31.
    Wybran, J., Fudenberg, H. H.: Thymus-derived rosette-forming cells in various human disease states: Cancer, lymphoma, bacterial and viral infection and other diseases. J. Clin. Invest. 52, 1026–1032 (1973).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • S. G. Taylor
  • G. A. Sisson
  • D. E. Bytell

There are no affiliations available

Personalised recommendations